Yankees to end Stroman’s Bronx tenure early with pre-break exit

Follow Us

Marcus Stroman’s pinstripe chapter is closing earlier than expected, as the Yankees are set to dump him before August.

What began as a promising depth acquisition has rapidly deteriorated into an untenable situation. The New York Yankees are preparing to part ways with veteran pitcher Marcus Stroman before mid-July’s All-Star festivities, possibly as early as late May, according to multiple sources within the organization familiar with the team’s internal deliberations.

Stroman, 33, arrived in New York during the 2023-24 offseason and was projected to provide reliable middle-rotation stability behind stars Gerrit Cole and Carlos Rodon. Instead, his brief tenure in pinstripes has spiraled dramatically, characterized by alarming statistical regression, health issues, and a problematic contract clause that could potentially burden the franchise with another year of financial commitment they’re increasingly unwilling to bear.

From rotation asset to roster liability

When acquiring Stroman, the Yankees envisioned securing a dependable ground-ball specialist whose pitching style would neutralize the home-run-friendly dimensions of Yankee Stadium. That expectation has proven wildly optimistic.

In just 9.1 innings pitched this season, Stroman has compiled a catastrophic 11.57 ERA, allowing 12 hits, 12 earned runs, and 7 walks across three abbreviated starts. His command issues have been particularly evident, with his signature sinker failing to generate the ground-ball outs that previously defined his effectiveness.

His ground-ball percentage—once among baseball’s elite—has plummeted to a career-worst 42.4%, while his strand rate sits at an abysmal 43.2%. Both metrics reveal a pitcher who can neither induce advantageous contact nor escape damage when runners reach base.

Contract trigger forcing organizational hand

Compounding Stroman’s on-field struggles is a contract stipulation that has organizational decision-makers increasingly concerned. Should the pitcher accumulate 140 innings during the 2025 campaign, a player option for 2026 worth approximately $18 million automatically activates.

Given his alarming performance metrics, the Yankees have virtually no appetite for such a scenario.

Stroman currently occupies a spot on the 15-day injured list with what manager Aaron Boone has characterized as “knee soreness.” While Boone recently indicated that the Yankees star continues experiencing discomfort, organizational sources suggest the extended IL placement serves dual purposes—allowing proper medical evaluation while simultaneously delaying more definitive roster decisions.

Nevertheless, sources with knowledge of the situation indicate a release or designation for assignment could materialize before July’s All-Star break, particularly as Luis Gil approaches his return and prospects like Brock Selvidge continue developing at Triple-A Scranton.

Emergency insurance, but unsustainable cost

At present, Stroman functions more as a catastrophic depth insurance than a viable rotation contributor. Given the Yankees’ already precarious pitching depth—with Gerrit Cole sidelined and Clarke Schmidt operating under workload restrictions—the team entered April with limited alternatives.

That reality likely preserved Stroman’s roster position initially, but as the bullpen solidifies and Max Fried establishes himself as the staff ace, organizational patience appears exhausted.

Triple-A options Kervin Castro and Zach Messinger have emerged as serviceable depth pieces, while several developing arms continue impressing at higher minor league levels. The writing on the wall becomes increasingly obvious with each start Stroman either misses or struggles through.

Rotation managing without Cole, options emerging

Despite Cole’s absence, the Yankees’ rotation has avoided complete collapse. Max Fried, Rodón, and Carlos Carrasco have provided sufficient stability to keep the team competitive. Boone’s strategic deployment of bullpen resources behind spot starters like Tim Hill has further mitigated rotation shortcomings.

Meanwhile, offensive production led by Aaron Judge, Ben Rice, and Paul Goldschmidt has powered the team to a respectable start, maintaining their standing within a relatively underwhelming AL East.

This buffer potentially affords general manager Brian Cashman the flexibility to sever ties with Stroman rather than risk an unexpected innings accumulation that would trigger his 2026 option.

Exit strategy: DFA or negotiated departure

A mid-season designation for assignment appears the most probable outcome, potentially followed by a mutual separation enabling Stroman to pursue opportunities elsewhere. Prolonged inactivity solely to avoid contractual obligations could potentially raise concerns from the players’ union.

Alternatively, a negotiated settlement or buyout arrangement might materialize once Stroman exits the injured list, facilitating a cleaner separation without additional financial exposure.

Regardless of procedural specifics, the fundamental conclusion remains inescapable: Stroman’s Bronx tenure approaches its conclusion.

Boone’s delicate message

Boone, typically protective of his players in public settings, has offered little reassurance regarding Stroman’s immediate future.

Earlier this week, Boone acknowledged that they were still monitoring Stroman’s response to treatment while noting he continues ramping up activities, though without establishing any concrete timeline for return.

Behind this cautious messaging, the organization appears to already formulating contingency plans that exclude Stroman.

The Yankees are expected to determine Stroman’s fate within approximately six weeks, with internal deadlines around the All-Star break serving as decision points. Should Gil and Schmidt return to full health while prospects like Selvidge continue developing, justification for retaining Stroman becomes increasingly untenable.

For an organization with championship aspirations, roster efficiency is paramount. Stroman simply hasn’t demonstrated sufficient value to warrant continued investment.

What do you think? Leave your comment below.

Follow Us